- The Global Vaccine Adjuvants Market was valued at USD 696.0 Million in 2020
- It is anticipated to reach USD 1400.1 Million by 2027
- A CAGR of 10.5% is anticipated over the forecast period
Vaccine adjuvants is known as non-specific immune-potentiators that give signals and activate immune-recognition pathways. Adjuvants are able to sustain and have robust immune responses to some bacteria and viruses for long duration. Adjuvants develops superior immune system in patients. Adjuvants is used to enhance the potency of vaccines.
Incorporation of an Adjuvants into a vaccine can amplify, guide and/or accelerate the immune response towards the most effective form for each infection or malignancy. They are essential components of subunit as well as certain inactivated vaccines as they induce specific immune responses that are more robust and long-lasting.
Sometimes Adjuvants containing vaccines can cause more local reactions like redness, swelling, and pain at the injection site. There are several adjutants are available such as aluminum, AS04, MF59, AS01B, CpG 1018. Most commonly used adjutants are aluminum salt-based adjutants and emulsion adjutants. Adjutants are used to enhance speed and duration of immune system.
Covid-19 has shown a positive on the growth of global vaccine adjuvants market as cases of covid-19 are rising and there is more demand of adjuvants vaccines all over the world. However, supply chains of vaccine distribution are disturbed due to lockdown in various countries which shows some decline impact as well but overall demand of vaccine.
Major players in the market are actively engaged in the discovery as well as development of new adjuvants for treating fatal diseases. Clinical trials are currently underway for products such as ISCOM & ISCOMMATRIX, AS01, and AS02, and the introduction of these new drugs is expected to drive growth in the market.
Some of the key players for global Vaccine Adjuvants Market are-
On the basis of type, the global vaccine adjuvants market is segmented as adjuvant emulsion, pathogen, combination, particulate, and others. The particulate type of agrochemical held the largest market share, comprising a wide range of products and offering greater efficiency against the diseases. Adjuvant emulsion held the second largest market share.
Particulate adjuvants include alum, virosomes, and cytokines. Alum, composed of aluminum salts, is widely used in hepatitis B and HPV vaccines. Virosomes, particles resembling noninfectious viruses, are used in vaccines such as hepatitis A, Epaxal, and Inflexal for influenza. Cytokines, proteins promoting the body's immune response, are employed in vaccines for hepatitis B, HPV, and herpes simplex virus. Interleukins, interferons, and granulocyte-macrophage colony-stimulating factor are among the cytokines used as adjuvants.
On the contrary, the pathogen type segment is predicted to be the fastest-growing over the forecast period. Monophosphoryl lipid A is one of the pathogenic adjuvants being tested, which is combined with alum to form the AS04 adjuvant used in the HPV-Cervarix vaccine.
On the basis of route of administration, adjuvants are categorized into oral, subcutaneous, intranasal, and intramuscular. The intramuscular segment held the biggest share of the global vaccine adjuvant market, due to its superior immune specificity compared to other routes of administration. These intramuscular vaccines are used for a variety of diseases, including HPV, influenza, and meningitis. However, the efficacy of the vaccine is contingent upon the type of route used for administration. For example, alum salts, which are the most commonly used parenteral adjuvants, cannot be administered orally or nasally and are therefore ineffective.
Among all the other segments, infectious diseases segment grabbed the highest market share of the global vaccine adjuvants market. The growing prevalence of infectious diseases and the increasing government investments are expected to drive the growth of the vaccine adjuvants market in the near future.
The global vaccine adjuvants market is segmented into North America, Europe, Asia-Pacific Latin America, and Middle East & Africa. North America is expected to dominate the market within the forecast period attributed to ongoing clinical trials for vaccine development, highly developed healthcare infrastructure and high investment in research & development activities in this region.
For example, according to NCT (National Clinical Trials) on September 2020, there are 500 clinical trials are under development in united states, which showing increase in demand of vaccine adjuvants market therefore ongoing clinical trials for vaccine development is propelling the growth of the market. In addition, increasing infectious diseases is also accelerating the growth of vaccine adjuvants market in this region. Moreover, growth in findings by government bodies, increasing prevalence of cancer disease and ongoing research activating of vaccine development also is boosting the growth of the market.
Asia Pacific is also expected to witness a high growth rate in vaccine adjuvants market due to increasing cases of covid-19 in this region. For example; according to Union health ministry, India recorded 1,31,968 new Covid-19 cases and number of infections reached to 13,06,0542 which indicates increasing demand of vaccine adjuvants market.
Factors such as increasing frequency of infectious diseases, rise in participation of pharma companies, growing geriatric population and supportive funding by government bodies are propelling growth of the market. Infectious diseases such as Ebola virus, SARS, MERS (Middle East Respiratory Syndrome) and currently on going Covid-19 pandemic are spreading rapidly all over the world. As all these are infectious diseases they can pass from person to person by direct or indirect contact. For example, according to WHO, globally there are 153,954,491 confirmed cases of covid-19, including 3,221,052 deaths.
In addition, key players launching new products is also propelling the growth of the market. Due to increasing demand of vaccine Adjuvants and increasing number of product offerings by key players of this market are also fostering the market growth. For instance; on May 2020, GlaxoSmithKline announced that it will produce one billion doses of pandemic vaccine Adjuvants in 2021 to support multiple Covid-19 vaccine collaborations.
However, side effects of some vaccine Adjuvants may hamper the growth of the market. In spite of that, advancement in Adjuvants technologies for the development of more effective vaccines can offer opportunities for further growth of the global vaccine adjuvants market.
The demand for adjuvants is expected to grow significantly as the focus on immunization against existing and emerging diseases increases. Adjuvant research has become increasingly important for the development of these products due to the inadequate immunogenicity of innovative vaccine antigens. Furthermore, the increasing use of recombinant and synthetic vaccines is anticipated to drive the growth of this market in the near future.
- On September 16th, 2020, Valneva and Dynavax Technologies announced a commercial partnership for the supply of Dynavax's CpG 1018 Adjuvants for use in Valneva's SARS-CoV-2 vaccine candidate, VLA2001. Valneva separately announced an agreement with the UK government to provide up to 190 million doses of VLA20011 over a five-year period. Dynavax will supply CpG 1018 to produce up to 100 million doses of vaccine in 2021. Valneva has the option to purchase up to an additional 90 million doses through 2025. Valneva expects VLA2001 to enter clinical studies by the end of 2020 and to potentially reach regulatory approval in the second half of 2021. This commercial supply partnership follows Valneva and Dynavax's initial collaboration to advance COVID-19 vaccine development, announced in April 2020.
- On May 12, 2021, CSL expressed its appreciation for the State Government Budget's commitment to establishing an Identity Box which will provide a robust and cost-effective way of safeguarding Australian IP, while also increasing investment in medical research. Through the use of this innovative policy, Australia will be able to promote and protect its medical research industry, and promote the production of home-grown medical products. This will help to create jobs, stimulate the economy, and support the development of new medical products. Furthermore, the Identity Box will ensure that Australian IP is protected from foreign producers and prevent foreign exploitation of Australia's valuable medical research.
|Historical data||2016 - 2021|
|Forecast Period||2022 - 2029|
|Market Size in 2020:||USD 696.0 Million|
|Base year considered||2021|
|Forecast Period CAGR %:||
|Market Size Expected in 2027:||USD 1400.1 Million|
|Tables, Charts & Figures:||175|
|Companies||Brenntag Biosector CSL Limited, SEPPIC Agenus, Inc. Novavax, Inc. SPI Pharma, Inc. Invivogen Avanti Polar Lipids Inc., MVP Laboratories Inc., OZ Biosciences , Adjuvatis, GlaxoSmithKline PLC, Croda International PLC, Merck KGaA, others.|
|Segments Covered||By Type, By Route Of Administration, By Disease|
|Regional Analysis||North America, U.S., Mexico, Canada, Europe, UK, France, Germany, Italy, Asia Pacific, China, Japan, India, Southeast Asia, South America, Brazil, Argentina, Columbia, The Middle East and Africa, GCC, Africa, Rest of the Middle East and Africa|
We are always looking to hire talented individuals with equal and extraordinary proportions of industry expertise, problem solving ability and inclination interested? please email us email@example.comJOIN US
BrandEssence® Market Research and Consulting Pvt ltd.
124, City Road, London EC1V 2NX
© Copyright 2023-24 BrandEssence® Market Research and Consulting Pvt ltd. All Rights Reserved | Designed by BrandEssence®